4 Cannabis Stocks With Recent News

The legal cannabis market is predicted to hit USD $146.4 billion globally by 2025, according to a report by Grand View Research. This rapid growth is propelled by increased cannabis legalization seen around the globe as well as the growing use of cannabis in several medical applications.

marijuanastocks.jpg

As far as the stock market is concerned, legal recreational cannabis will account for as much as 61% of the industry overall, with the other 39% going to medicinal cannabis as well as the black market. Despite this, many cannabis stocks have been able to make quite a name for themselves given the massive amount of momentum and propensity toward future growth that the cannabis industry has shown over the last few years.

Leafbuyer Technologies, Inc. (LBUY)a leading cannabis technology and marketing platform, announced the launch of its innovative delivery technology to complement its mobile application. This week a preliminary beta launch will begin to include that dispensaries in states such as California, Arizona, Nevada, and Washington are now able to add delivery to their list of offerings through Leafbuyer’s Greenlight mobile app.

“The addition of this new technology will allow us to monetize our consumer base through a fee generated from each transaction,” said Kurt Rossner, CEO. “We’ll be able to penetrate thousands of new dispensaries and delivery companies in legal markets by offering this delivery solution. Leafbuyer will not physically deliver the products, rather we will hand off the ‘last mile’ to our delivery and dispensary partners.”

Leafbuyer reported that its quarterly cash sales growth increased 36% year over year in the quarter ending March 31, 2019, attributing its growth to platform enhancements. The platform allows consumers to order cannabis products ahead, earn loyalty points, and cut the line to pick up and pay at numerous participating dispensaries, and now delivery. The company recently launched a Los Angeles satellite office, which will become the primary regional office for several Western states, allowing sales initiatives to be more heavily focused on newly legal Midwestern and Eastern states.

Aphria Inc. (APHA), a Canadian cannabis company, announced it has closed its private placement offering of $300 million of 5.25% convertible senior notes due 2024 and that initial purchasers fully exercised their option to buy up to an additional $50 million of notes, resulting in gross proceeds of $350 million.  The company plans to use the net proceeds to support its international expansion initiatives, for future acquisitions as well as general corporate purposes.

This followed the news that its German subsidiary Aphria Deutschland GmbH has secured the previously announced license for the domestic cultivation of medical cannabis from the German Federal Institute for Drugs and Medical Devices and was granted a cultivation license for four of the nine total lots awarded.

“Aphria thanks the BfArM for their diligent examination and validation of our approach for domestic cultivation with this license,” said Hendrik Knopp, Managing Director of Aphria Germany. “Construction on our 8,000 square meter indoor cultivation facility is already underway and we anticipate it will be fully operational by Summer 2020. We are pleased to additionally support German patients in the upcoming months with high-quality imported cannabis flower and oils from Denmark and Canada.”

Aurora Cannabis Inc. (ACB), a world leading cannabis company, announced its contract with the German Federal Institute for Drugs and Medical Devices has been finalized allowing Aurora to begin construction on a new state of the art indoor cannabis production facility this May.

“We are thrilled with the positive outcome of the tender process, and excited to start construction on our latest production facility,” said Neil Belot, Chief Global BDO. “In addition to providing German medical patients with a local supply of high-quality, medical grade cannabis, this new facility will also bring additional new jobs to the German labour market. It’s a strong validation of our production and distribution standards to have been recognized as having the highest-rated overall concept out of 79 tender applications, and we look forward to continuing to increase availability of medical cannabis in this important market.”

This news followed the company entering a binding letter agreement with Hempco Food and Fiber Inc. (HEMP), a provider of hemp-based foods, fiber and nutraceuticals.  The agreement entails that Aurora will acquire all of the issued and outstanding common shares, not already owned, of Hempco at$1.04 per share in common shares of Aurora, for a valuation of C$63.4 million.

Canopy Growth Corporation (CGC) (WEED), a world-leading diversified cannabis and hemp company, announced last week it would acquire US cannabis company Acreage Holdings, Inc. (ACRGF) in a $3.4 billion cash and stock deal that will close if and when cannabis production and sales are legal at the federal level in the US.

“Today we announce a complex transaction with a simple objective,” Co-Chief Executive Bruce Linton said. “Our right to acquire Acreage secures our entrance strategy into the United States as soon as a federally permissible pathway exists. By combining Acreage’s management team, licenses and assets with Canopy Growth’s intellectual property and brands, there will be tremendous value creation for both companies’ shareholders.”

Following the news of this potential deal, a GMP Securities’ analyst upgraded Canopy Growth from Hold to Buy with a price target raised from $65 to $72.

marijuana.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018, and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam has been compensated an additional $100,000 by Leafbuyer Technologies for a period of coverage from April 12, 2019 to June 12, 2019. Midam owned 77,000 shares of Leafbuyer Technologies. Midammay buy or sell additional shares of (LBUY) in the open market at any time (as of 3/29/2019) Midam Ventures no longer owns 77,000 shares of (LBUY), including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc. Click here for full Midam disclaimer.

Advertisements

4 Cannabis Stocks Heating Up The Markets

The cannabis sector gained one if its biggest votes of confidence to date when top Wall Street firm Bank of America -Merrill Lynch initiated coverage on four of the top cannabis stocks with mostly positive outlook for sector.  BofA is the latest of the Wall Street firms to add cannabis to their coverage, following the likes of Cowen, Jefferies and Piper Jaffray.

cannabisstocks.jpg

Cannabis stocks, for the most part, have started the year off on a strong foot with the Horizons’ Marijuana Life Sciences ETF (HMMJ) (HMLSF), the largest and most representative cannabis exchange traded fund, up about 45%.  As the cannabis sector continues to break new boundaries, investors seeking opportunities in the budding sector may benefit from keeping tabs on several cannabis stocks.

Leafbuyer Technologies, Inc. (LBUY), a leading cannabis technology and marketing platform that connects consumers to dispensaries and product companies, announced the establishment of the company’s first satellite office in Los Angeles, California. The new office is in addition to its original Denver Colorado headquarters and will become the primary regional office for several western states. This move will help Leafbuyer expand its national footprint by enabling sales initiatives to focus on newly legal Midwestern and Eastern states.

“California is now a mature recreational and medical cannabis market, which makes this the opportune time to establish a secondary operation in the southern part of this industry-leading state,” said Kurt Rossner, CEO.

Leafbuyer recently announced that its quarterly cash sales growth rose 36% year over year in the quarter ending March 31, 2019. The cannabis stock attributes this success to platform enhancements, order ahead and Leafbuyer loyalty as well as a multi-state sales team.  The platform allows consumers to order cannabis products ahead, earn loyalty points, and cut the line to pick up and pay at numerous participating dispensaries Leafbuyer plans to continue to expand its reach into newly legal US markets, while increasing consumer retention to boost bottom line revenues.

Canopy Growth Corporation (CGC) (WEED), a world-leading diversified cannabis and hemp company, is rumored to be preparing to purchase Acreage Holdings Inc, a U.S. cannabis company, by buying the right to purchase, according to Bloomberg and CNBC.  If Canopy Growth was to acquire the US-based cannabis company now, it would be delisted from the TSE since cannabis is illegal in the U.S., and the exchange does not allow companies to own stakes in businesses that run illegal operations.  Instead, Canopy Growth will purchase the rights to buy Acreage if or when cannabis becomes legal in the U.S. at an agreed-upon price, according to the source.

Bank of America (BAC) initiated new coverage Canopy Growth giving it a buy rating with a price target of $52.  On Tuesday, Co-CEO Bruce Linton updated the company’s revenue guidance at a cannabis conference in Toronto in which Canopy is anticipating at least $744 million in revenue in fiscal 2020, beating analyst estimates by 19 percent. The company also announced the completion of an all-cash acquisition of Spain-based licensed cannabis producer Cáñamo y Fibras Naturales, S.L. (Cafina). The acquisition paves the way for Canopy to expand its European production footprint.

“Operating multiple production assets within Europe will allow us to increase revenue in the EU free of supply constraints,” commented Mark Zekulin, President & Co-CEO. “This strategic acquisition in a scalable, low-cost production environment diversifies our owned production capabilities in Europe, similar to our approach in Canada where we have production facilities in seven different provinces. Adding Cafina will allow us to quickly build out our presence in Spain using its existing cultivation licence as a launch pad, while ensuring our Canadian footprint – the largest in the world – can continue to serve the medical and recreational needs of Canadians.”

HEXO Corp (HEXO), consumer packaged goods cannabis company, had Bank of America (BAC) initiated coverage on the stock giving it a buy rating and the title of its top cannabis stock pick.  Most recently, the company announced reaching a significant milestone of completing the first harvest in its 1 million sq. ft. expansion.

“Completing the first harvest in our 1,000,000 sq. ft. greenhouse expansion showcases the dedication and hard work of the entire HEXO team,” said Sébastien St-Louis, CEO and co-founder. “We are very proud of our continued ability to execute on our plans, creating value for our shareholders and demonstrating our commitment to our customers. This cultivation milestone means that an expanded HEXO product offering will be available to more Canadians shortly.”

In mid-March, HEXO announced a definitive arrangement agreement to acquire Newstrike Brands Ltd. (NWKRF) in a stock deal valued C$263 million ($196.7 million). This acquisition which will boost HEXO’s production capacity to 150,000 kg annually while increasing its domestic market access to 9 provinces.

Aurora Cannabis Inc. (ACB), a world leading cannabis company, also had Bank of America (BAC) initiate coverage on it stock giving it a buy rating and price target of $11. The company announced that, further to its April 5th press release, the public appeal process related to the German cannabis production tender has been completed, and Aurora’s contract with the German Federal Institute for Drugs and Medical Devices has been finalized allowing Aurora to begin construction on a new indoor cannabis production facility in May.

“We are thrilled with the positive outcome of the tender process, and excited to start construction on our latest production facility,” said Neil Belot, Chief Global Business Development Officer. “We are very proud of the work done by our European team.  In addition to providing German medical patients with a local supply of high-quality, medical grade cannabis, this new facility will also bring additional new jobs to the German labour market. It’s a strong validation of our production and distribution standards to have been recognized as having the highest-rated overall concept out of 79 tender applications, and we look forward to continuing to increase availability of medical cannabis in this important market.”

Also this week, Aurora announced entering a binding letter agreement with Hempco Food and Fiber Inc. (HEMP), a provider of hemp-based foods, fiber and nutraceuticals.  Per the agreement, Aurora will acquire all of the issued and outstanding common shares not already owned of Hempco and pay $1.04 per share in common shares of Aurora, for a valuation of C$63.4 million.

marijuanastocks.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018, and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam has been compensated an additional $100,000 by Leafbuyer Technologies for a period of coverage from April 12, 2019 to June 12, 2019. Midam owned 77,000 shares of Leafbuyer Technologies. Midammay buy or sell additional shares of (LBUY) in the open market at any time (as of 3/29/2019) Midam Ventures no longer owns 77,000 shares of (LBUY), including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc. Click here for full Midam disclaimer.

4 Marijuana Stocks To Watch This Week

The Horizons’ Marijuana Life Sciences ETF (HMMJ) (HMLSF) is the largest and most representative marijuana exchange traded fund in the markets. The fund strives to duplicate, to an extent, the performance of the North American Marijuana Index (NAMI). The NAMI was designed to track the performance of a basket of North American life sciences companies with a focus of their operations in the marijuana industry.

marijuana.jpg

Marijuana stocks, for the most part, have started the year off on a strong note as this marijuana ETF has risen 45% year to date.  As lawmakers advocate for legislative changes in favor of marijuana legalization and the adoption of marijuana for medical purposes rises, the sector has responded favorably.  Investors seeking opportunities in th budding  marijuana sector may benefit from keeping tabs on several marijuana stocks.

Leafbuyer Technologies, Inc. (LBUY), a leading cannabis technology and marketing platform that connects consumers to dispensaries and product companies, announced that its quarterly cash sales growth rose 36% year over year in the quarter ending March 31, 2019. The company attributes this success to mainly to platform enhancements, order ahead and Leafbuyer loyalty as well as a multi-state sales team.  The company’s go forward plan is to continue to expand into newly legal US markets, while increasing consumer retention to boost bottom line revenues.

“This growth provides momentum and a solid foundation for 2019. As we increase our national footprint and expand our industry leading platform, we’re forecasting significant sales gains through the remainder of the year,” said Kurt Rossner, CEO.

Last month. Leafbuyer announced that the number of its Greenlight platform users has reached nearly 80,000.  The platform allows consumers to order cannabis products ahead, earn loyalty points, and cut the line to pick up and pay at participating dispensaries. At the time of this news release, the number of Leafbuyer dispensary clients with capabilities grew to 60 dispensaries, located throughout the states of California, Colorado, Oklahoma, and Michigan.

Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the health & wellness, announced that it has been working to resolve its 9.5% convertible notes due April 2019 and intends to repay the notes with cash from a business transaction as well as the net proceeds of a planned equity investment from long-term investor Foris Ventures.

“We are pleased with the support of our long term investors in supporting our plans to pay off this debt,” said John Melo, Amyris President and CEO. “We believe this pathway toward retiring our April 2019 debt should mitigate some of the dilutive impact on equity and we will provide more details and an update when this process is complete.”

At the end of March, Amyris announced stated it will discuss at an April 15 conference its previously disclosed cannabinoid development, licensing and commercialization agreement containing $300 million of R&D and milestone payments and a long-term royalty stream. Since, the company reached its first milestone for its cannabinoid partner, LAVVAN. They brought in the first payment of $10 million, which is part of a $300 million collaboration before future royalty payments.

Aphria Inc. (APHA) , a leading global cannabis company, announced fiscal third-quarter earnings reporting a loss as the company booked a C$58 million impairment charge and an additional C$30 million in operating losses. For the quarter ended Feb. 28th, Aphria reported a loss of $0.20 per share, compared to earnings of $0.08 per share for the year earlier.  However, the company reported that total revenue grew by 617% to $73.6 million compared to the $10.3 million the year prior.

“Our organization has experienced significant change in a very short period of time which was necessary to propel the Company forward. Aphria will continue to drive sustainable long-term shareholder value by leveraging its strong brand positioning, superior distribution model, product innovation, industrial scale cultivation and automation, medical-use leadership and strategic global platform” stated Irwin D. Simon, Chairman and Interim CEO.

The company also provided an update that it has entered into a series of transactions that will accelerate the expiration of an unsolicited takeover offer from Green Growth Brands to April 25. The transactions will provide up to an additional $89 million of liquidity without dilution to shareholders, according to the company.

Aurora Cannabis Inc. (ACB), a world leading cannabis company, provided an update on the status of Aurora Sun, the company’s latest and largest Sky Class facility which is currently under construction in Alberta. Aurora Sun will now be expanded by 33% from its original plans totaling to 1.62 million square feet to meet consumer demands. Aurora projects an expected production capacity at Aurora Sun in excess of 230,000 kg of high-quality cannabis annually.

“Aurora Sun represents the next evolution in our Sky Class facility design, delivering massive scale, low cost production, and consistent, high-quality cannabis,” said Terry Booth, CEO. “The increased scale of Aurora Sun reflects our expectations for the long-term growth in global demand, especially the higher margin international medical markets which will be faced with significant supply shortages for the foreseeable future. Sun is also designed with flexibility in mind to enable us to quickly meet changing market demands, particularly as breeding and cultivation technologies evolve and as customer preferences and requirements change.”

cannabisstocks1.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018, and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam has been compensated an additional $100,000 by Leafbuyer Technologies for a period of coverage from April 12, 2019 to June 12, 2019. Midam may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc.. Click here for full Midam disclaimer.

4 Healthcare Stocks To Focus On Today

The global healthcare market is forecast to hit $53.65 billion by 2025, according to a report by Grand View Research. There are several factors accountable for driving the growth of the healthcare industry such as the reduction of healthcare spending among hospitals and providers, improved technology and the rising use of data-enriched products like mHealth, eHealth, Electronic Health Records and mobile apps.

healthcarestocks.jpg

Multi-Trillion Dollar Industry Providing Massive Opportunity In 2019 & Beyond 

The report detailed, “with the combination of artificial and human intelligence data analytics, which offer wide opportunities to further customize medical approaches, the demand for these tools is anticipated to increase over the forecast period”.

Healthcare companies seeking to develop innovative and effective solutions to advance the quality of care could catalyze opportunities for investors looking to healthcare stocks.

Premier Health Group (PHGRF) (PHGI.CN)a company focused on innovative healthcare approaches that combine human skill-based expertise with emerging technologies, announced that further to its previous news release, it has entered into a share purchase agreement to acquire two cash flow positive Metro Vancouver pharmacies. The pharmacies had combined annual revenue of approximately $6 million for the fiscal year ended August 31, 2018, and Premier Health expects to complete the acquisition during Q2 2019.

“We are very excited about this opportunity to acquire two well-run and profitable pharmacies.  As part of our patient centric model, fill and fulfillment is a major component of our telemedicine app.  We are also pleased to have the pharmacies’ key management team, with over 20 years’ of combined experience managing pharmacies, come on board to continue running operations. In light of our recent announcement of our medical cannabis decision tool for our JUNO EMR clients, our pharmacists will be able to help with patient education and support regarding medical cannabis” said Dr. Essam Hamza, CEO. “In addition, with one of the pharmacies occupying a space of over 6,000 square feet, we have the potential to open a new medical and/or cannabis clinic within the existing space.”

This news followed the announcement that the company has initiated integration of CB2 Insights’ (CBII.CN) medical cannabis Clinical Decision Support (CDS) tool to provide Premier Health’s over 4600 physicians using its Juno EMR platform access to the industry’s sole medical cannabis-specific CDS tool. Premier Health has also recently partnered with Bio Conscious Technologies (BCT) to bring their artificial intelligence (AI) technology to Premier Health’s user base for improved monitoring and management of chronic conditions, such as diabetes.

Avinger, Inc. (AVGR), a commercial stage medical device company, announced that it has received 510(k) clearance from the U.S. FDA for its Pantheris SV (Small Vessel) image-guided atherectomy system, a product line extension of its Lumivascular image-guided atherectomy platform.  The Pantheris SV device is designed for the diagnosis and treatment of Pulmonary Artery Disease (PAD) in small vessels, 2 to 4 millimeters in diameter, with its lower profile and longer length.

“We are excited to receive U.S. pre-marketing clearance for Pantheris SV, which we believe could expand our addressable market for atherectomy procedures by as much as 50%,” said Jeff Soinski, Avinger’s President and CEO. “With the clearance of this new device, we are well-positioned to build on the positive momentum we have seen in our Pantheris business since the introduction of the next-generation system in 2018. Following our anticipated limited launch of Pantheris SV, we plan on leveraging our growing commercial infrastructure and installed base of Lumivascular accounts to efficiently scale up the introduction of Pantheris SV and drive growth of our Pantheris product family in the second half of 2019.”

Back in October, the device received CE Marking and the first patients were treated with the device in Germany in November.  Avinger plans to have a limited launch of the device in several U.S. sites when commercial product is available.  According to the company, this new device is expected to increase the available market for the company up to 50%.

Precipio, Inc. (PRPO), a specialty diagnostics company, announced that it is negotiating a definitive agreement with a manufacturer to produce its patented IV-Cell media.  According to the company, the manufacturing partner comes with experience and large volume manufacturing capabilities.  Furthermore, it has the embedded quality-control processes, and the various ISO-related certifications required to mass-produce the media for global distribution.

“This is an exciting time for us, as we move towards the start of commercializing the technologies we’ve developed,” said Ilan Danieli, CEO. “The company and its shareholders deserve to reap the benefits of the innovative products developed, as we translate ideas in the laboratory into products – and revenue, for the company.”

This news followed the announcement of Methodist Hospital, of Memphis, TN, selecting Precipio’s HemeScreen assay for use in its molecular hematology testing laboratory. HemeScreen’s average turnaround time is 2- 4 days, compared to 2 weeks. According to the company, this deal may generate between $50-100K in revenue annually.

Hemispherx Biopharma, Inc.  (HEB), an immuno-pharma R&D and emerging commercial growth company, announced the first participant received initial dosing in its clinical trial sponsored by Roswell Park Comprehensive Cancer Center evaluating the company’s experimental drug Ampligen® (rintatolimod) in combination with Merck’s Keytruda® (pembrolizumab) for the treatment of metastatic triple-negative breast cancer.

“We are very excited to see the first patient treated as part of this important clinical trial evaluating Ampligen in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. We could not ask for better partners than the world-class team at Roswell Park Comprehensive Cancer Center, as we seek to evaluate the impact of the combined therapy on this high risk and very sick patient population,” said CEO Thomas K. Equels.

“Our extensive work with Ampligen has led many top oncologists to conclude, including in peer reviewed medical journal articles, that Ampligen has the potential to change the tumor microenvironment. Making tumors easier targets for checkpoint blockade therapies creates an exciting new approach with the potential to significantly improve clinical outcomes for patients in multiple solid tumor cancer types.”

biotechstocks.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. Midam owns zero shares of Premier Health Group Inc., which they purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Today’s Trending Cannabis Stocks

The cannabis industry is projected to grow to $50 billion by 2029 from $17 billion in 2019, according to analyst firm Jefferies.  The firm’s estimate includes the Canadian markets, the United States’ thirty-three medicinal markets and seventeen recreational markets, Europe’s twelve-country medical market, Latin America’s five-country medical and 2-country recreational market as well as three other countries with a legal medical market.

cannabisstocks.jpg

Jefferies analyst Owen Bennett, Jefferies analyst believes that the firm’s projection is “probably conservative,” and that a “realistic upside scenario” may be a global cannabis market as large as $130 billion by 2029. “This assumes full U.S. federal legalization, full recreational and medical legalization across Europe, full medical and recreational legalization across Lat Am, and cannabis disruption of a number of other industries,” Bennett added.

While the cannabis industry continues to show strength and sentiment surrounding stocks in the sector remains positive, investors may continue to find opportunities in cannabis stocks.

ParcelPal Technology Inc. (PTNYF) (PKG) (FSE: PT0), a technology-driven logistics company purposed with connecting consumers to the goods they love within an hour, announced it will be hosting an investor update conference call on May 17th, 2019 to review recent progress. The company also announced that it will be releasing its quarterly financial statements for Q4 FY2018 by April 30, 2019.

This followed the news of achieving a major milestone, the completion of over 2 million deliveries.  The company’s plans to move forward include more joint ventures, expansion on its technology and to push its platform on multiple consumer verticals, while expanding operations across Canada and into the U.S. ParcelPal is in the final stages of launching medical and recreational cannabis delivery in Canada with Choom Holdings (CHOOF) and recently signed Kiaro.  This on-demand cannabis delivery plan is expected to begin in April 2019, with more details to follow, and is expected to drive additional users to the platform and open fresh markets.

President and CEO Kelly Abbott states, “We are extremely excited to have achieved this major milestone. Our growth in 2018 was tremendous and our team has grown significantly. We are looking forward to a successful rollout in the cannabis industry amongst other verticals in the coming months across Canada with existing and future partnerships.”

Aurora Cannabis Inc. (ACB) announced that the company has appointed Carey Squires as its Executive Vice President of Corporate Development and Strategy. In this newly created role, reporting to the Executive Chairman, Mr. Squires in collaboration with senior executives across

“With deep experience in the U.S. and Canadian capital markets, Carey has been a trusted advisor to Aurora on a variety of growth initiatives, including our recently successful capital raise,” said Michael Singer, Executive Chairman. “In this new position, Carey will be a core member of Aurora’s senior management team, executing on the development of key strategic initiatives, including partnerships and M&A opportunities. We look forward to working closely with Carey to leverage his extensive knowledge in the execution of our investor development, international growth and partnership strategies, sourcing potential accretive opportunities in the global cannabis industry and negotiating favourable business transactions.”

This followed the news of the filing on Tuesday of a preliminary short-form base shelf prospectus with Canadian securities regulators and a corresponding shelf registration statement on Form F-10 with the U.S. Securities and Exchange Commission.  When made effective, this will allow Aurora to issue stock offerings, debt securities, subscription receipts, units or warrants for an aggregate value of up to $750 million during a period of 25 months, according to the company.

Charlotte’s Web Holdings, Inc. (CWBHF) (CWEB), a market share leader in hemp-derived CBD extract products, reported financial results for Q4 and year ended December 31, 2018. Fourth quarter highlights included: retail doors increased over 80% to 3680 and 57% of revenue came from ecommerce, organic consolidated revenue growth of 71% to $21.5 million, and gross profit increased 63% to $16.3 million, or 76% of consolidated revenue. Highlights of 2018 Full Year Results included: organic revenue growth of 74% to $69.5 million, gross profit increased 75% to $52.3 million, and adjusted EBITDA decreased to 30% from 36% of consolidated revenue.

“During the fourth quarter we concentrated our efforts on completing the 2018 harvest and building product inventory to support growing consumer demand. Our 2018 harvest resulted in 675,000 pounds of raw hemp compared to 63,000 pounds in 2017. This inventory build ensures we are able to meet growing demand and supply the large national retail chains that are beginning to carry our products. In general, broader consumer awareness of the benefits of cannabinoids, namely cannabidiol (CBD) from hemp extract, is driving increased uptake in all product categories in our retail channels and e-commerce platform,” stated Hess Moallem, President and CEO.

Charlotte’s Web has been actively adding additional retail distribution customers and locations and recently surpassed 4,000 locations after national retail chains began carrying its products.  Several new products and formats are planned for 2019 in animal nutrition, wellness topicals and human consumables, according to the company.

marijuanastocks.jpeg


This Blog is an affiliate of MIDAM VENTURES LLC.  Midam has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Midam owns zero shares. Click Here For Full Disclaimer

3 Healthcare Stocks That May Keep Your Portfolio Healthy

As medical experts and scientists discover diseases, healthcare companies are ready to tackle these challenges by developing top-quality treatments.   Because of this, the healthcare sector manages to remain above the curve, which in turn leads to growth.  According Deliotte, global health expenditures are forecast to rise as healthcare spending is expected to increase 5.4% annually between 2017-2022, amounting to $10.059 trillion.

healthcarestocks.jpg

“The emergence of personalized medicine, increased use of exponential technologies, entry of disruptive and non-traditional competitors, the demand for expanded care delivery sites, and revamped payment and public funding models are all impacting the financial performance of the health care ecosystem. The health care market is looking to health technology for help.”

With chronic diseases running rampant, the demand for innovative healthcare solutions is rising rapidly.  As healthcare companies are working to develop fresh and innovative approaches, whether it be technology, devices or drugs, several healthcare stocks are beginning to see higher activity in the markets.

Premier Health Group (PHGRF) (PHGI.CN) , focuses on innovative healthcare approaches that combine human skill-based expertise with emerging technologies, announced it has initiated integration of CB2 Insights’ (CBII.CN) medical cannabis Clinical Decision Support (CDS) tool.  This agreement provides Premier Health’s over 4600 physicians using its Juno EMR platform access to the industry’s sole medical cannabis-specific CDS tool, which is designed to include medical cannabis into patient treatment plans and overcome barriers from a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy while remaining on a patient-centered basis using clinically-validated data.

“We are dedicated to finding new ways to create value for our physician network,” said Dr. Essam Hamza, CEO. “We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”

This news followed the company’s announcement partnering Bio Conscious Technologies (BCT) to bring their artificial intelligence (AI) technology to Premier Health’s user base for improved monitoring and management of chronic conditions, such as diabetes.  The integration of BCT’s algorithm DiaBits into Premier Health’s patient-centric app can learn an individual’s physiology and with machine learning technology predict where their blood sugar will trend over time based on their past.

AVEO Oncology Inc (AVEO) announced financial results earlier this month for the full year ended December 31, 2018 and a business update. The company reported narrowing its Q4 net loss per share to $0.03, from $0.08 the year prior and saw revenue increase to $1.48 million from the previous year’s $82,000. AVEO stated that it believes that its $24.4 million in cash, cash equivalents, and marketable securities at the end of 2018 combined with the $7.5 million from sales under an agreement with SVB Leerink should allow it to fund planned operations into Q1 2020.

Furthermore, last month the company presented top-line results from the TIVO-3 trial, AVEO’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in 350 subjects with refractory advanced or metastatic renal cell carcinoma at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium.

“The results of TIVO-3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and tolerability profile among VEGF TKIs in the treatment of kidney cancer,” said Michael Bailey, President CEO. “We continue to believe that there is a significant potential commercial opportunity for an active and well tolerated therapy within the third plus line of therapy, particularly one that demonstrated activity in a highly refractory patient population that has received prior PD-1 treatment. We are hopeful that the positive PFS outcomes from TIVO-3 translate into an improved overall survival hazard ratio and look forward to reporting a more mature interim OS outcome in the fourth quarter of 2019.”

Amarin Corporation plc (AMRN) announced that the American Diabetes Association® (ADA) issued important updates to the Standards of Medical Care in Diabetes for 2019 which include updates related to the results of the REDUCE-IT™ cardiovascular outcomes study. The REDUCE-IT related updates were informed by newly published research covering REDUCE-IT results.

The Standards of Care update references the drug, icosapent ethyl, which is studied in Amarin’s REDUCE-IT that evalutes Vascepa® (icosapent ethyl) capsules. Vascepa has been approved for use by the US FDA as an aide to diet to reduce triglyceride levels for severe hypertriglyceridemia. Amarin has begun transmission of data to the FDA to support the submission of a supplemental new drug application to expand Vascepa’s FDA label based on the landmark REDUCE-IT results.

“As we have commenced transmission of data to the FDA for the submission of our sNDA seeking an expansion of the Vascepa label based on the landmark REDUCE-IT results, we are pleased by ADA’s acknowledgement of the importance of the REDUCE-IT results in its 2019 update of the Standards of Care,” said Craig B. Granowitz, M.D., Ph.D., SVP, CMO. “The medical community will also hopefully take note of recent research reporting the prevalence of, and increased costs associated with, diabetes mellitus and high triglyceride levels despite statin therapy5.”

healthcarestocks1.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. Midam owns zero shares of Premier Health Group Inc., which they purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

3 Marijuana Stocks Making Headlines

North America is by far the leader of the cannabis industry, as it is not only the fastest growing region but also possesses the largest market share.  Canada became the first G7 nation to legalize adult-use recreational cannabis and the influx of United States legalizing one form or another of cannabis as well the passing of the 2018 US Farm Bill, which legalized hemp, is driving the growth of the sector. The two countries, together, command the global cannabis industry, which is forecast to hit $146.4 billion across the globe by 2025, with a compound annual growth rate of 34.6%, according to a Grand View Research report.

marijuana.jpg

The increased legalization of cannabis along with the growing utilization in several medical applications are key factors for driving the growth of the industry.   As the cannabis industry continues to evolve, there are several marijuana stocks making headlines.

Leafbuyer Technologies, Inc. (LBUY) announced that the number of Greenlight platform users has reached nearly 80,000, further to its recent release announcing Leafbuyer’s launch of the Greenlight app in Colorado and Oklahoma. The platform permits consumers to order cannabis products ahead, earn loyalty points, and cut the line to pick up and pay at participating dispensaries. Presently, the number of Leafbuyer dispensary clients with capabilities has grown to a total of 60, located throughout the states of California, Colorado, Oklahoma, and Michigan.

“The rapid geographic implementation of the Greenlight technology and the large number of users is encouraging. Developments are under way to bring new features to the platform that are expected to be a catalyst for continued revenue growth,” said Kurt Rossner, CEO of Leafbuyer. “We plan to expand the footprint further and optimize this technology to make it a staple in every legal market across the country.”

This news followed the announcement that Leafbuyer and Greenlight now integrate with Flowhub’s point of sale and compliance technology, giving customers have access to immediate, up-to-date menu information regarding product availability in dispensaries using Flowhub API and Leafbuyer platforms.

Curaleaf Holdings, Inc. (CURLF) (CURA.CN) on its recent earnings conference, company executives said CVS Health Corp (CVS) will start offering its Curaleaf Hemp lotions and transdermal patches in around 800 stores across the U.S. Today the company annouced the opening of its 23rd Florida dispensary as it continues to expand rapidly throughout the state. Curaleaf has the largest cannabis dispensary footprint in the US, now with 43 dispensaries across the country.

“As Curaleaf continues to deliver on its expansion strategy, we are well positioned to improve the quality of patients’ lives by providing access to safe top-quality cannabis products,” shared Joe Lusardi, Curaleaf CEO.

The dispensary includes the community’s first medical marijuana drive-thru. Curaleaf was the first in the state to introduce and test the drive-thru concept at its Palm Harbor dispensary and since has launched a second drive-thru in Orlando.   Today, Curaleaf also announced it will celebrate its grand opening on Thursday, March 21 from 3pm until 7pm at its Gainesville dispensary.

Canopy Growth Corporation (CGC) (WEED) announced it has acquired AgriNextUSA, a hemp enterprise led by CEO Geoff Whaling, to accelerate Canopy Growth’s entry into key American jurisdictions. As previously mentioned, Canopy Growth is on track to build the first Hemp Industrial Park in the Southern Tier of New York State, after receiving a state license to produce and process hemp. Canopy growth committed to invest $100M to $150M into a hemp operation as well as the production of high-quality CBD products.

“The United States is the next stop on Canopy Growth’s desired path to becoming a leading, revenue-generating company focused on all aspects of cannabinoids and their potential,” said Bruce Linton, co-CEO and Chairman. “Our significant investments, acquisitions and compilation of talented leaders such as Geoff will position us for swift expansion throughout the United States. By collaborating with a pioneer like Geoff, who has been involved with our team since our earliest days in 2013, we will aim to turn hemp supplied by American farmers into a wide range of products.”

This news followed Canopy’s announcement earlier this week of a two-year processing and extraction agreement Wednesday with HollyWeed Manufacturing & Extracts Inc.  The agreement entails that HollyWeed will process Canopy-supplied dried cannabis flower in its and in turn, HollyWeed will supply Canopy with oil and resin extracted from the source material. The companies expect the first shipment of product for extraction will take place in fall of 2019.

marijuanastocks.jpg


This blog is an affiliate of Midam Ventures, LLC. Pursuant to an agreement between Midam Ventures LLC and Leafbuyer Technologies Inc., Midam is being paid $50,000 for a period of 30 days beginning November 1, 2018 and ending November 30, 2018. Midam has been paid an additional $50,000 and 40,000 common restricted shares of Leafbuyer Technologies, Inc. extending the contract another 30 days ending December 31, 2018. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to January 31, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to March 1, 2019. Midam has been compensated an additional $50,000 by Leafbuyer Technologies and has extended its period of coverage to April 1, 2019. Midam owns 77,000 shares of Leafbuyer Technologies. Midam may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Leafbuyer Technologies Inc. Click here for full Midam disclaimer.